Tempero MA (2019) NCCN guidelines updates: pancreatic cancer. J Natl Compr Canc Netw 17:603–605

PubMed  CAS  Google Scholar 

Yip D, Karapetis C, Strickland A, Steer CB, Goldstein D (2006) Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. Cochrane Database Syst Rev 19:3 (CD002093)

Google Scholar 

Sultana A, Smith CT, Cunningham D, Starling N, Neoptolemos JP, Ghaneh P (2007) Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 25:2607–2615

Article  PubMed  Google Scholar 

Bilimoria KY, Bentrem DJ, Ko CY, Ritchey J, Stewart AK, Winchester DP et al (2007) Validation of the 6th edition AJCC pancreatic cancer staging system: report from the National Cancer Database. Cancer 110:738–744

Article  PubMed  Google Scholar 

Ueno H, Ikeda M, Ueno M, Mizuno N, Ioka T, Omuro Y et al (2016) Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol 77:595–603

Article  PubMed  CAS  Google Scholar 

Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369:1691–1703

Article  Google Scholar 

Goldstein D, El-Maraghi RH, Hammel P, Heinemann V, Kunzmann V, Sastre J et al (2015) nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Natl Cancer Inst 107:dju413

Article  PubMed  Google Scholar 

Saito Y, Takekuma Y, Oshino T, Sugawara M (2022) Combination of mirogabalin and duloxetine attenuates peripheral neuropathy by eribulin: a novel case report. Case Rep Oncol 15:606–610

Article  PubMed  PubMed Central  Google Scholar 

Flatters SJL, Dougherty PM, Colvin LA (2017) Clinical and preclinical perspectives on chemotherapy-induced peripheral neuropathy (CIPN): a narrative review. Br J Anaesth 119:737–749

Article  PubMed  CAS  Google Scholar 

Jordan B, Margulies A, Cardoso F, Cavaletti G, Haugnes HS, Jahn P et al (2020) Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO clinical practice guidelines for diagnosis, prevention, treatment and follow-up. Ann Oncol 31:1306–1319

Article  PubMed  CAS  Google Scholar 

Molassiotis A, Cheng HL, Leung KT, Li YC, Wong KH, Au JSK et al (2019) Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy. Brain Behav 9:e01312

Article  PubMed  PubMed Central  Google Scholar 

Johnson C, Pankratz VS, Velazquez AI, Aakre JA, Loprinzi CL, Staff NP et al (2015) Candidate pathway-based genetic association study of platinum and platinum-taxane related toxicity in a cohort of primary lung cancer patients. J Neurol Sci 349:124–128

Article  PubMed  PubMed Central  CAS  Google Scholar 

Mizrahi D, Park SB, Li T, Timmins HC, Trinh T, Au K et al (2021) Hemoglobin, body mass index, and age as risk factors for paclitaxel- and oxaliplatin-induced peripheral neuropathy. JAMA Netw Open 4:e2036695

Article  PubMed  PubMed Central  Google Scholar 

Vincenzi B, Frezza AM, Schiavon G, Spoto C, Silvestris N, Addeo R et al (2013) Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV. Support Care Cancer 21:1313–1319

Article  PubMed  Google Scholar 

Brydøy M, Oldenburg J, Klepp O, Bremnes RM, Wist EA, Wentzel-Larsen T et al (2009) Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors. J Natl Cancer Inst 101:1682–1695

Article  PubMed  PubMed Central  Google Scholar 

Hershman DL, Till C, Wright JD, Awad D, Ramsey SD, Barlow WE et al (2016) Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants 65 years or older in Southwest Oncology Group Clinical Trials. J Clin Oncol 34:3014–3022

Article  PubMed  PubMed Central  CAS  Google Scholar 

Jordan K, Feyer P, Höller U, Link H, Wörmann B, Jahn F (2017) Supportive treatments for patients with cancer. Dtsch Arztebl Int 114:481–487

PubMed  PubMed Central  Google Scholar 

Catalano M, Ramello M, Conca R, Aprile G, Petrioli R, Roviello G (2022) Risk factors for nab-paclitaxel and gemcitabine-induced peripheral neuropathy in patients with pancreatic cancer. Oncology 100:384–391

Article  PubMed  CAS  Google Scholar 

Blomstrand H, Scheibling U, Bratthäll C, Green H, Elander NO (2019) Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer. BMC Cancer 19:40

Article  PubMed  PubMed Central  Google Scholar 

Aogi K, Takeuchi H, Saeki T, Aiba K, Tamura K, Iino K et al (2021) Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis. Int J Clin Oncol 26:1–17

Article  PubMed  Google Scholar 

Abraxane® (nanoparticle albumin-bound paclitaxel) [package insert on the internet]. Tokyo; Taiho pharmaceutical Co., https://www.info.pmda.go.jp/go/pack/4240409D1023_1_15/?view=frame&style=XML&lang=ja. Accessed 19 Apr 2024

Sugimoto M, Takagi T, Suzuki R, Konno N, Asama H, Sato Y et al (2021) Mirogabalin vs pregabalin for chemotherapy-induced peripheral neuropathy in pancreatic cancer patients. BMC Cancer 21:1319

Article  PubMed  PubMed Central  CAS  Google Scholar 

Loprinzi CL, Lacchetti C, Bleeker J, Cavaletti G, Chauhan C, Hertz DL et al (2020) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. J Clin Oncol 38:3325–3348

Article  PubMed  Google Scholar 

Molassiotis A, Cheng HL, Lopez V, Au JSK, Chan A, Bandla A et al (2019) Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy. BMC Cancer 19:132

Article  PubMed  PubMed Central  Google Scholar 

Cavaletti G, Alberti P, Frigeni B, Piatti M, Susani E (2011) Chemotherapy-induced neuropathy. Curr Treat Options Neurol 13:180–190

Article  PubMed  Google Scholar 

Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE et al (2011) Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 29:4548–4554

Article  Google Scholar 

Saito Y, Takekuma Y, Kobayashi M, Komatsu Y, Sugawara M (2021) Detection of risk factors related to administration suspension and severe neutropenia in gemcitabine and nab-paclitaxel treatment. Support Care Cancer 29:3277–3285

Article  PubMed  Google Scholar 

Avan R, Janbabaei G, Hendouei N, Alipour A, Borhani S, Tabrizi N et al (2018) The effect of pregabalin and duloxetine treatment on quality of life of breast cancer patients with taxane-induced sensory neuropathy: a randomized clinical trial. J Res Med Sci 23:52

Article  PubMed  PubMed Central  Google Scholar 

Salehifar E, Janbabaei G, Hendouei N, Alipour A, Tabrizi N, Avan R (2020) Comparison of the efficacy and safety of pregabalin and duloxetine in taxane-induced sensory neuropathy: a randomized controlled trial. Clin Drug Investig 40:249–257

Article  PubMed  CAS  Google Scholar 

Misawa S, Denda T, Kodama S, Suzuki T, Naito Y, Kogawa T et al (2023) Efficacy and safety of mirogabalin for chemotherapy-induced peripheral neuropathy: a prospective single-arm trial (MiroCIP study). BMC Cancer 23:1098

Article  PubMed  PubMed Central  CAS  Google Scholar 

Chan A, Hertz DL, Morales M, Adams EJ, Gordon S, Tan CJ et al (2019) Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview. Support Care Cancer 27:3729–3737

Article  PubMed  PubMed Central  Google Scholar